13 tulemused
OBJECTIVE
To determine intravitreal and plasma concentrations and retinal toxicity after transcorneal intravitreal injection of 1 μg and 2 μg of topotecan (Hycamtin).
METHODS
Twelve healthy albino rabbits were included in this in vivo experiment. Six anesthetized albino rabbits received a single
OBJECTIVE
To report two rare cases of encephaloclastic cyst induced by intraventricular topotecan. To share our experience in diagnosing and treating this rare disease.
BACKGROUND
Ommaya reservoirs provide fast access and reliable drug delivery to cerebral spinal fluid. They are routinely utilized
OBJECTIVE
To identify the maximum tolerated dose and dose-limiting toxicity of periocular topotecan in patients with relapsed or resistant intraocular retinoblastoma who are facing imminent enucleation.
METHODS
For this phase I study, a starting dose of 0.5 mg of periocular topotecan administered
OBJECTIVE
To examine the tolerability and antitumor activity of trebananib plus pegylated liposomal doxorubicin (PLD) or topotecan in recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
METHODS
In this open-label phase 1b study, patients received trebananib 10 mg/kg or 15
Convection-enhanced delivery (CED) for the treatment of malignant gliomas is a technique that can deliver chemotherapeutic agents directly into the tumor and the surrounding interstitium through sustained, low-grade positive-pressure infusion. This allows for high local concentrations of drug within
BACKGROUND
Treatment of eyes with retinoblastoma failing systemic chemoreduction and external beam radiotherapy is seldom efficacious. This study compares the efficacy and toxicity of intra-arterial ophthalmic artery chemotherapy (IAO) to our historical cohort of sequential periocular and systemic
Posterior reversible encephalopathy syndrome (PRES) has been associated with the use of several medications, including chemotherapeutic agents.A 65-year-old woman was diagnosed with adenocarcinoma of the ovary, after sixth-line treatment with topotecan, at To use our intra-arterial chemotherapy (IAC) rabbit model to assess the impact of IAC procedure, drug, dose, and choice of technique on ocular structure and function, to study the nature and etiology of IAC toxicity, and to compare to observations in OBJECTIVE
To investigate on the safety and efficacy of intravitreous chemotherapy for retinoblastoma seeding in a relatively large cohort and provide information on the necessary number of injections and long-term control.
METHODS
Retrospective interventional case series of 40 consecutive eyes with
OBJECTIVE
To report on our 3-year experience with the use of superselective ophthalmic artery infusion of chemotherapy as initial, primary treatment for intraocular retinoblastoma.
METHODS
Prospective, institutional review board-approved clinical trial.
METHODS
Twenty-eight eyes of 23 newly
UNASSIGNED
To evaluate the effectiveness and complications of intra-arterial chemotherapy (IAC) for treating advanced refractory retinoblastoma (RB) in a large single-center cohort.
UNASSIGNED
Eighty-four eyes of 62 consecutive patients with advanced refractory RB who received IAC were included in
BACKGROUND
The feasibility and results of intraarterial chemotherapy, also termed ophthalmic artery chemosurgery (OAC), for retinoblastoma in less developed countries have seldom been reported.
METHODS
A retrospective evaluation of a program of OAC in Argentina from 2010 to
OBJECTIVE
To analyze our 5-year experience of intra-arterial chemotherapy (IAC) for retinoblastoma as primary or secondary therapy.
METHODS
Retrospective interventional case series.
METHODS
A total of 70 eyes of 67 patients.
METHODS
Ophthalmic artery chemotherapy infusion under fluoroscopic guidance